Literature DB >> 22460412

Laryngeal and tracheobronchial involvement in Wegener's granulomatosis.

Ascedio Jose Rodrigues1, Marcia Jacomelli, Renata Xavier Baldow, Carmen Valente Barbas, Viviane Rossi Figueiredo.   

Abstract

INTRODUCTION: Wegener's granulomatosis (WG) is a form of systemic vasculitis that involves primarily the upper and lower airways and the kidneys. The most frequent airway manifestations include subglottic stenosis and inflammation, and tracheal and bronchial stenoses. The endoscopic visualization of the airways is the best tool for assessing, diagnosing and managing those changes.
OBJECTIVES: To describe the endoscopic abnormalities found in the airway mucosa of a group of patients with WG undergoing bronchoscopy at Hospital das Clínicas of the Faculdade de Medicina, Universidade de São Paulo (HC-FMUSP), and to report the therapeutic bronchoscopic interventions used in some cases.
METHODS: The study assessed 15 patients diagnosed with GW from the Vasculitis Outpatient Clinic of the Department of Pulmonology, HC-FMUSP, referred for bronchoscopy at the Service of Respiratory Endoscopy, HC-FMUSP, from 2003 to 2007.
RESULTS: Fifteen patients were studied [11 females (73.33%)]; mean age, 34 ± 11.5 years. Airway changes were found in 80% of the patients, and the most frequent endoscopic finding was subglottic stenosis (n = 6). Therapeutic bronchoscopy was performed in three patients with subglottic stenosis and in other three patients with bronchial stenosis, all showing good results.
CONCLUSION: Bronchoscopy allows for diagnosing, monitoring, and treating the airway lesions in WG, being a minimally invasive therapeutic option in selected cases.

Entities:  

Mesh:

Year:  2012        PMID: 22460412

Source DB:  PubMed          Journal:  Rev Bras Reumatol        ISSN: 0482-5004


  1 in total

1.  Thoracic manifestation of Wegener's granulomatosis: Computed tomography findings and analysis of misdiagnosis.

Authors:  Jiakai Li; Chuangui Li; Jiaojiao Li
Journal:  Exp Ther Med       Date:  2018-05-11       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.